| Overview |
| bs-7538R-FITC |
| TRIB3 Polyclonal Antibody, FITC Conjugated |
| FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Rat |
| Mouse, Dog, Cow, Pig, Horse, Chicken, Rabbit |
| Specifications |
| FITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human TRIB3 |
| 201-300/358 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 57761 |
| Nucleus |
| C20orf97; Neuronal cell death inducible putative kinase; Neuronal cell death-inducible putative kinase; NIPK; p65 interacting inhibitor of NF-kappaB; p65-interacting inhibitor of NF-kappa-B; SINK; SKIP 3; SKIP3; TRB 3; TRB-3; TRB3; TRIB 3; Trib3; TRIB3_HUMAN; Tribbles homolog 3; Tribbles3. |
| Disrupts insulin signaling by binding directly to Akt kinases and blocking their activation. May bind directly to and mask the 'Thr-308' phosphorylation site in AKT1. Binds to ATF4 and inhibits its transcriptional activation activity. Interacts with the NF-kappa-B transactivator p65 RELA and inhibits its phosphorylation and thus its transcriptional activation activity. Interacts with MAPK kinases and regulates activation of MAP kinases. May play a role in programmed neuronal cell death but does not appear to affect non-neuronal cells. Does not display kinase activity.Tissue specificity:Highest expression in liver, pancreas, peripheral blood leukocytes and bone marrow. Also highly expressed in a number of primary lung, colon and breast tumors. Expressed in spleen, thymus, and prostate and is undetectable in other examined tissues, including testis, ovary, small intestine, colon, leukocyte, heart, brain, placenta, lung, skeletal muscle, and kidney. |
| Application Dilution |
| FCM |
1:20-100 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz